Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald G Wulf

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Bone Marrow Transplantation|December 20, 2024
Comparison of fludarabine/melphalan (FM140) with fludarabine/melphalan/BCNU (FBM110) in patients with relapsed/refractory AML undergoing allogeneic hematopoietic cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working PartyJesús Duque-Afonso, Jürgen Finke, Maud Ngoya, et al.
Bone Marrow Transplantation|June 19, 2026
The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL)Anna Ossami Saidy, Ariane Boumendil, Peter Dreger, et al.
Frontiers in Immunology|October 13, 2023
Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working partyOlaf Penack, Christophe Peczynski, Christian Koenecke, et al.
Molecular Cancer Research : MCR|March 13, 2020
Destruction of a Microtubule-Bound MYC Reservoir during Mitosis Contributes to Vincristine's Anticancer ActivitySabrina Becker, Christina Kiecke, Eva Schäfer, et al.
Blood|October 9, 2009
Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow TransplantationNicolaus Kröger, Ernst Holler, Guido Kobbe, et al.
Bone Marrow Transplantation|October 8, 2021
Correction: Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT surveyLeopold Sellner, Johannes Schetelig, Linda Koster, et al.
British Journal of Haematology|February 29, 2020
Outcome of allogeneic haematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable: a retrospective study by the Chronic Malignancies Working Party of the EBMTDonal P McLornan, Vittoria Malpassuti, Anne Lippinkhof-Kozijn, et al.
Bone Marrow Transplantation|May 24, 2020
Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT surveyLeopold Sellner, Johannes Schetelig, Linda Koster, et al.
Haematologica|April 23, 2026
Long-term outcome of allogeneic hematopoietic cell transplantation for T-cell prolymphocytic leukemia - a study on behalf of the Chronic Malignancies Working Party of the EBMTJoanna Drozd-Sokolowska, Luuk Gras, Laurien G A Baaij, et al.
Bone Marrow Transplantation|August 12, 2023
Current incidence, severity, and management of veno-occlusive disease/sinusoidal obstruction syndrome in adult allogeneic HSCT recipients: an EBMT Transplant Complications Working Party studyTapani Ruutu, Christophe Peczynski, Mohamed Houhou, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Bone Marrow Transplantation|December 20, 2024
Comparison of fludarabine/melphalan (FM140) with fludarabine/melphalan/BCNU (FBM110) in patients with relapsed/refractory AML undergoing allogeneic hematopoietic cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working PartyJesús Duque-Afonso, Jürgen Finke, Maud Ngoya, et al.
Bone Marrow Transplantation|June 19, 2026
The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL)Anna Ossami Saidy, Ariane Boumendil, Peter Dreger, et al.
Frontiers in Immunology|October 13, 2023
Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working partyOlaf Penack, Christophe Peczynski, Christian Koenecke, et al.
Molecular Cancer Research : MCR|March 13, 2020
Destruction of a Microtubule-Bound MYC Reservoir during Mitosis Contributes to Vincristine's Anticancer ActivitySabrina Becker, Christina Kiecke, Eva Schäfer, et al.
Blood|October 9, 2009
Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow TransplantationNicolaus Kröger, Ernst Holler, Guido Kobbe, et al.
Bone Marrow Transplantation|October 8, 2021
Correction: Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT surveyLeopold Sellner, Johannes Schetelig, Linda Koster, et al.
British Journal of Haematology|February 29, 2020
Outcome of allogeneic haematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable: a retrospective study by the Chronic Malignancies Working Party of the EBMTDonal P McLornan, Vittoria Malpassuti, Anne Lippinkhof-Kozijn, et al.
Bone Marrow Transplantation|May 24, 2020
Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT surveyLeopold Sellner, Johannes Schetelig, Linda Koster, et al.
Haematologica|April 23, 2026
Long-term outcome of allogeneic hematopoietic cell transplantation for T-cell prolymphocytic leukemia - a study on behalf of the Chronic Malignancies Working Party of the EBMTJoanna Drozd-Sokolowska, Luuk Gras, Laurien G A Baaij, et al.
Bone Marrow Transplantation|August 12, 2023
Current incidence, severity, and management of veno-occlusive disease/sinusoidal obstruction syndrome in adult allogeneic HSCT recipients: an EBMT Transplant Complications Working Party studyTapani Ruutu, Christophe Peczynski, Mohamed Houhou, et al.
Pageof 5